Xuelin (Steve) Wang
A seasoned lawyer in China’s equity and debt capital markets. With a Ph.D. in cell biology, trusted adviser to leading biotech and healthcare companies in Hong Kong and US IPOs.
Steve has extensive experience representing issuers and underwriters in international capital markets transactions, with a particular focus on biotechnology and healthcare companies. He has advised on more than 50 initial public offerings in the healthcare sector, as well as numerous follow-on equity offerings, investment grade and high yield debt offerings, and complex liability management transactions.
Steve holds a Ph.D. in cell biology, which enables him to bring a rare combination of scientific depth and capital markets expertise to advising biotech and healthcare clients on their most important and transformative transactions. He is a trusted advisor to companies across the full lifecycle, from pre-IPO and growth stage companies to established public issuers. In addition to his core biotech and healthcare practice, his experience spans a variety of other industries, including technology, consumer and retail.
Steve was recognized as a “Rising Star” at the 2021 China Law & Practice Awards and the 2020 IFLR Asia-Pacific Awards.
Experience
Hong Kong Equity Capital Markets
- Initial public offerings by METiS TechBio, Mabwell Bioscience, InSilico Medicine, GenFleet Therapeutics, Medtide, PegBio, Mirxes, Visen Pharmaceuticals, BrainAurora Medical Technology, HighTide Therapeutics, WuXi XDC, Laekna, Cutia Therapeutics, MedSci Healthcare, Biocytogen Pharmaceuticals, Yonghe Medical, CANbridge Pharmaceuticals, MicroTech Medical, Abbisko, Broncus, Kindstar Global, HUTCHMED, Zylox-Tonbridge, CARsgen Therapeutics, Antengene, RemeGen, JW Therapeutics, Tigermed, Zai Lab, Ocumension Therapeutics, Akeso, InnoCare Pharma, Venus Medtech, CStone Pharmaceuticals, Innovent Biologics, BeiGene, Ping An Good Doctor and 3SBio
U.S. Equity Capital Markets
- Initial public offerings and follow-on offerings by Ascentage Pharma, Adagene, Gracell Biotechnologies, Genetron, I-Mab, Zai Lab, BeiGene, ECMOHO, 9F, Douyu, Cango, Uxin, iClick, Rise Education and Edwards Group
Debt Capital Markets
- Investment-grade and MTN notes offerings by China Oceanwide International Financial Management, China Orient Asset Management, Asia Standard International, JD.com, Baidu, PPL Corporation, CSX Corporation, Kennametal, China Forestry Group, China Petrochemical, Greenland Hong Kong, Republic of Indonesia, China Cinda Asset Management, Pertamina and Bangkok Bank
- High-yield notes offerings by Fantasia, Zhenro Properties Group, West China Cement, KWG Property, Guorui Properties, SOCAM Development, China South City, CIFI, PT Cikarang Listrindo, China SCE Property, Times Property, Redco Properties, Central China Real Estate, Fosun International Limited and Dufry AG
- Consent solicitations and tender offers for SOCAM Development, Times Property, Redco Properties, Country Garden, SOHO China, Central China Real Estate and K. Hovnanian Enterprises
Insights
News
Recognition
Chambers Greater China Region – Capital Markets: Equity (International Firms), China
IFLR1000 – Capital Markets, M&A, Financial and Corporate, Hong Kong, Highly Regarded
China Law & Practice Awards – “Rising Star Lawyer of the Year,” 2021
IFLR Asia-Pacific Awards – “Rising Star,” 2020
Education
- magna cum laude
- Order of the Coif
- Articles Editor, Minnesota Journal of Law, Science & Technology
Qualifications and admissions
- Hong Kong
- State of New York